Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorGORWOOD, P.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBENICHOU, Jacques
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOORE, Nicholas
dc.contributor.authorALVAREZ MARTINEZ, E.
dc.contributor.authorMERTENS, J.
dc.contributor.authorAGUGLIA, E.
dc.contributor.authorFIGUEIRA, M. L.
dc.contributor.authorFALKAI, P.
dc.contributor.authorOLIVIER, V.
dc.contributor.authorWATTEZ, M.
dc.contributor.authorPICAREL-BLANCHOT, F.
dc.contributor.authorDE BODINAT, C.
dc.date.accessioned2021-03-22T14:23:03Z
dc.date.available2021-03-22T14:23:03Z
dc.date.issued2020-09-25
dc.identifier.issn1099-1077 (Electronic) 0885-6222 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26777
dc.description.abstractEnOBJECTIVE: The present observational cohort study documented the safety of agomelatine in current medical practice in out-patients suffering from major depressive disorder. METHOD: The 6-month evolution of agomelatine-treated patients was assessed with a focus on safety (emergent adverse events, liver acceptability), severity of depression using the Clinical Global Impression Severity (CGI-S) score, and functioning measured by the Sheehan Disability Scale (SDS). RESULTS: A total of 8453 depressed patients from 761 centres in 6 countries were analysed (female: 67.7%; mean age: 49.1 ± 14.8 years). Adverse events reported were in accordance with the known safety profile of agomelatine. Cutaneous events were reported in 1.7% of the patients and increased hepatic transaminases values were reported in 0.9 % of the patients. The incidence of events related to suicide/self-injury was 1.0%. Two completed suicides, not related to the study drug, were reported. CGI-S total scores and SDS sub-scores improved and numbers of days lost or underproductive decreased over the treatment period. CONCLUSIONS: In standard medical practice, agomelatine treatment was associated with a low incidence of side effects. No unexpected events were reported. A decrease in the severity of the depressive episode and improved functioning were observed. TRIAL REGISTRATION NAME: Observational cohort study to evaluate the safety of agomelatine in standard medical practice in depressed patients. A prospective, observational (non-interventional), international, multicentre cohort study. TRIAL REGISTRATION NUMBER: ISRCTN53570733.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enThe safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study
dc.title.alternativeHum Psychopharmacolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/hup.2759en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32976677en_US
bordeaux.journalHuman Psychopharmacology: Clinical and Experimentalen_US
bordeaux.pagee2759en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Human%20Psychopharmacology:%20Clinical%20and%20Experimental&rft.date=2020-09-25&rft.spage=e2759&rft.epage=e2759&rft.eissn=1099-1077%20(Electronic)%200885-6222%20(Linking)&rft.issn=1099-1077%20(Electronic)%200885-6222%20(Linking)&rft.au=GORWOOD,%20P.&BENICHOU,%20Jacques&MOORE,%20Nicholas&ALVAREZ%20MARTINEZ,%20E.&MERTENS,%20J.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée